Innogenetics, Abbott Strike $9.5M Deal On HCV Patent
Gent, Belgium-based Innogenetics said the agreement would grant Abbott a nonexclusive license to sell hepatitis C virus genotyping products based on real-time technologies. In exchange, Innogenetics will receive royalties for each hepatitis C test that Abbott sells worldwide during the patent term.
Abbott will also receive access to key Innogenetics patents...
To view the full article, register now.